Presidio Pharmaceuticals, Inc.
Records under this name other than the patents Presidio Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Showing 1 to 10 of 10 · Back to Presidio Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,614,207 | Inhibitors of hepatitis C virus Lapsed on the fee record Ended Dec 24, 2021 · USPTO record | Lapsed on the fee record | Ended Dec 24, 2021 | USPTO record |
| US 9,309,260 | Inhibitors of hepatitis C virus Lapsed on the fee record Ended Apr 12, 2020 · USPTO record | Lapsed on the fee record | Ended Apr 12, 2020 | USPTO record |
| US 9,150,554 | Fused ring inhibitors of hepatitis C Lapsed on the fee record Ended Oct 6, 2019 · USPTO record | Lapsed on the fee record | Ended Oct 6, 2019 | USPTO record |
| US 9,120,779 | Inhibitors of HCV NS5A Lapsed on the fee record Ended Sep 1, 2019 · USPTO record | Lapsed on the fee record | Ended Sep 1, 2019 | USPTO record |
| US 9,085,587 | Inhibitors of hepatitis C virus Lapsed on the fee record Ended Jul 21, 2019 · USPTO record | Lapsed on the fee record | Ended Jul 21, 2019 | USPTO record |
| US 8,999,967 | Tricyclic fused ring inhibitors of hepatitis C Lapsed on the fee record Ended Apr 7, 2019 · USPTO record | Lapsed on the fee record | Ended Apr 7, 2019 | USPTO record |
| US 8,877,707 | Inhibitors of HCV NS5A Lapsed on the fee record Ended Nov 4, 2018 · USPTO record | Lapsed on the fee record | Ended Nov 4, 2018 | USPTO record |
| US 8,865,756 | Inhibitors of HCV NS5A Lapsed on the fee record Ended Oct 21, 2018 · USPTO record | Lapsed on the fee record | Ended Oct 21, 2018 | USPTO record |
| US 8,822,520 | Substituted bicyclic HCV inhibitors Lapsed on the fee record Ended Sep 2, 2018 · USPTO record | Lapsed on the fee record | Ended Sep 2, 2018 | USPTO record |
| US 8,709,999 | Substituted bicyclic HCV inhibitors Lapsed on the fee record Ended Apr 29, 2018 · USPTO record | Lapsed on the fee record | Ended Apr 29, 2018 | USPTO record |